Key points are not available for this paper at this time.
The instability of a breast cancer subtyping scheme like PAM50 could have important consequences in clinical management of patients. AIMS is a fully stable and robust subtyping scheme that recapitulates PAM50.
Paquet et al. (Thu,) studied this question.